Activation of the innate immune system by the endogenous ligand hyaluronan

Current Opinion in Organ Transplantation

Volumn 13, Issue 1, 2008, Pages 20-25

  Shirali, Anushree C ^a   Goldstein, Daniel R ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b 3 FMP ^*  (United States)

Author keywords

Endogenous ligand; Hyaluronan; Innate immunity

Indexed keywords

HERMES ANTIGEN; HYALURONIC ACID; LIGAND; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4;

ADAPTIVE IMMUNITY; DENDRITIC CELL; GRAFT REJECTION; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; LYMPHOCYTE FUNCTION; NONHUMAN; ORGAN TRANSPLANTATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD44; GRAFT REJECTION; HYALURONIC ACID; IMMUNITY, NATURAL; REPERFUSION INJURY; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; TRANSPLANTATION; TRANSPLANTATION IMMUNOLOGY;

EID: 38149062127     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3282f3df04     Document Type: Review

References (50)

1. Obhrai J, Goldstein DR. The role of Toll-like receptors in solid organ transplantation. Transplantation 2006; 81:497-502.
2. Goldstein DR, Tesar BM, Akira S, Lakkis FG. Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. J Clin Invest 2003; 111:1571-1578.
3. Tesar BM, Zhang J, Li Q, Goldstein DR, et al. TH1 immune responses to fully MHC mismatched allografts are diminished in the absence of MyD88, a Toll-like receptor signal adaptor protein. Am J Transplant 2004; 4:1429-1439.
4. Hirschfeld M, Ma Y, Weis JH, et al. Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine Toll-like receptor 2. J Immunol 2000; 165:618-622.
5. Beg AA. Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses. Trends Immunol 2002; 23:509-512.
6. Goldstein DR. The identity of innate immune activators in organ transplantation: origins from within or exterior to the host? Am J Transplant 2007; 7:1692-1694.
7. Kogan G, Soltes L, Stern R, et al. Hyaluronic acid: a natural biopolymer with a broad range of biomedical and industrial applications. Biotechnol Lett 2007; 29:17-25. A good review focusing on the myriad of uses for hyaluronan in medicine and biotechnology.
8. Harada H, Takahashi M. CD44-dependent intracellular and extracellular catabolism of hyaluronic acid by hyaluronidase-1 and -2. J Biol Chem 2007; 282:5597-5607. This work shows that the degradation of hyaluronan in transfected cell lines by human hyaluronidases is CD44 dependent and principally mediated by Hyal-1 and Hyal-2.
9. Almond A. Hyaluronan. Cell Mol Life Sci 2007; 64:1591-1596.
10. Lee JY, Spicer AP. Hyaluronan: a multifunctional, megaDalton, stealth molecule. Curr Opin Cell Biol 2000; 12:581-586.
11. McKee C, Penno M, Cowman M, et al. Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages: the role of HA size and CD44. J Clin Invest 1996; 98:2403-2413.
12. Stern R, Asari AA, Sugahara KN. Hyaluronan fragments: an information-rich system. Eur J Cell Biol 2006; 85:699-715.
13. Lo GH, LaValley M, McAlindon T, et al. Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis. JAMA 2003; 290:3115-3121.
14. Hamilton TK. Assessing nonsurgical options for facial restoration. Dermatol Ther 2007; 20 (Suppl 1):S5-S9.
15. Iavazzo C, Athanasiou S, Pitsouni E, et al. Hyaluronic acid: an effective alternative treatment of interstitial cystitis, recurrent urinary tract infections, and hemorrhagic cystitis? Eur Urol 2007; 51:1534-1540.
16. Noble PW, Jiang D. Matrix regulation of lung injury, inflammation, and repair: the role of innate immunity. Proc Am Thorac Soc 2006; 3:401-404.
17. Gotte M, Yip GW. Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res 2006; 66:10233-10237.
18. Verkoelen CF, Verhulst A. Proposed mechanisms in renal tubular crystal retention. Kidney Int 2007; 72:13-18.
19. Fraser JR, Laurent TC, Laurent UB. Hyaluronan: its nature, distribution, functions and turnover. J Intern Med 1997; 242:27-33.
20. Harris EN, Kyosseva SV, Weigel JA, et al. Expression, processing, and glycosaminoglycan binding activity of the recombinant human 315-kDa hyaluronic acid receptor for endocytosis (HARE). J Biol Chem 2007; 282:2785-2797. This article characterizes the ligand binding properties, function, and location of the human hyaluronic acid receptor in a transfected cell line.
21. Stern R, Kogan G, Jedrzejas MJ, et al. The many ways to cleave hyaluronan. Biotechnol Adv 2007; 25:537-557. An excellent in-depth description of the known enzymatic and nonenzymatic methods of generating hyaluronan fragments.
22. Soltes L, Mendichi R, Kogan G, et al. Degradative action of reactive oxygen species on hyaluronan. Biomacromolecules 2006; 7:659-668.
23. Hallgren R, Gerdin B, Tengblad A, et al. Accumulation of hyaluronan (hyaluronic acid) in myocardial interstitial tissue parallels development of transplantation edema in heart allografts in rats. J Clin Invest 1990; 85:668-673.
24. Hallgren R, Gerdin B, Tufveson G. Hyaluronic acid accumulation and redistribution in rejecting rat kidney graft: relationship to the transplantation edema. J Exp Med 1990; 171:2063-2076.
25. Wallander J, Hallgren R, Scheynius A, et al. Intestinal distribution of hyaluronan in small bowel allografting in the rat. Transpl Int 1993; 6:133-137.
26. Wells A, Larsson E, Hanas E, et al. Increased hyaluronan in acutely rejecting human kidney grafts. Transplantation 1993; 55:1346-1349.
27. Rao PN, Zeevi A, Snyder J, et al. Monitoring of acute lung rejection and infection by bronchoalveolar lavage and plasma levels of hyaluronic acid in clinical lung transplantation. J Heart Lung Transplant 1994; 13:958-962.
28. Lorant T, Tufveson G, Johnsson C. The graft content of hyaluronan is increased during xenograft rejection. Xenotransplantation 2004; 11:269-275.
29. Johnsson C, Tufveson G. Serum hyaluronan: a potential marker of cardiac allograft rejection? J Heart Lung Transplant 2006; 25:544-549.
30. Knoflach A, Azuma H, Magee C, et al. Immunomodulatory functions of low-molecular-weight hyaluronate in an acute rat renal allograft rejection model. J Am Soc Nephrol 1999; 10:1059-1066.
31. Taylor KR, Gallo RL. Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. FASEB J 2006; 20:9-22.
32. Siegelman M, DeGrendele H, Estess P. Activation and interaction of CD44 and hyaluronan in immunological systems. J Leukoc Biol 1999; 66:315-321.
33. Rouschop KM, Roelofs JJ, Sylva M, et al. Renal expression of CD44 correlates with acute renal allograft rejection. Kidney Int 2006; 70:1127-1134.
34. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003; 4:33-45.
35. Teder P, Vandivier RW, Jiang D, et al. Resolution of lung inflammation by CD44. Science 2002; 296:155-158.
36. Bollyky PL, Lord JD, Masewicz SA, et al. Cutting edge: high molecular weight hyaluronan promotes the suppressive effects of CD4+CD25+ regulatory T cells. J Immunol 2007; 179:744-747. This is the first study to demonstrate that activated regulatory T cells bind high-molecular-weight hyaluronic acid, which increases their suppressor function. It suggests that regulatory T cells may sense tissue integrity and accordingly dampen the inflammatory response.
37. Termeer CC, Hennies J, Voith U, et al. Oligosaccharides of hyaluronan are potent activators of dendritic cells. J Immunol 2000; 165:1863-1870.
38. Termeer C, Benedix F, Sleeman J, et al. Oligosaccharides of hyaluronan activate dendritic cells via Toll-like receptor 4. J Exp Med 2002; 195:99-111.
39. Taylor KR, Trowbridge JM, Rudisill JA, et al. Hyaluronan fragments stimulate endothelial recognition of injury through TLR4. J Biol Chem 2004; 279:17079-17084.
40. Jiang D, Liang J, Fan J, et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 2005; 11:1173-1179.
41. Scheibner KA, Lutz MA, Boodoo S, et al. Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J Immunol 2006; 177:1272-1281.
42. Tesar BM, Jiang D, Liang J, et al. The role of hyaluronan degradation products as innate alloimmune agonists. Am J Transplant 2006; 6:2622-2635. This work confirms that LMW hyaluronan activates dendritic cells via a TIRAP-dependent pathway, but independently of MyD88 and TRIF.
43. O'Neil LA, Bowie AG. The family of five: TIR-domain-containing adaptors in toll-like receptor signaling. Nat Rev Immunol 2007; 7:353-364.
44. Mummert ME, Mohamadzadeh M, Mummert DI, et al. Development of a peptide inhibitor of hyaluronan-mediated leukocyte trafficking. J Exp Med 2000; 192:769-780.
45. Wu H, Chen G, Wyburn KR, et al. TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest 2007; 117:2847-2859. This article demonstrates that a murine model of IRI is associated with and dependent on increased TLR4 expression in renal tubular epithelial cells. The investigators also show the upregulation of multiple endogenous ligands including hyaluronan.
46. Tesar BM, Goldstein DR. Acute allograft rejection occurs independently of inducible heat shock protein-70. Transplantation 2007; 83:1513-1517. This study found that HSP-70 is not sufficient for in-vitro activation of dendritic cells and is not associated with acute rejection in a murine skin allograft model.
47. Taylor KR, Yamasaki K, Radek KA, et al. Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on Toll-like receptor 4, CD44, and MD-2. J Biol Chem 2007; 282:18265-18275. This study described that the specific activation of TLR4 by LMW hyaluronan requires interaction between TLR4 and a specific accessory TLR signaling molecule, MD2. This interaction is augmented by but not dependent upon CD44.
48. Liang J, Jiang D, Griffith J, et al. CD44 is a negative regulator of acute pulmonary inflammation and lipopolysaccharide-TLR signaling in mouse macrophages. J Immunol 2007; 178:2469-2475. Liang et al. describe a novel immune 'gatekeeper' function for CD44 in response to LPS activation of TLR4. In the absence of CD44, fewer negative regulators of TLR signaling are expressed.
49. Hascall VC, Majors AK, De La Motte CA, et al. Intracellular hyaluronan: a new frontier for inflammation? Biochim Biophys Acta 2004; 1673:3-12.
50. Toole BP. Hyaluronan promotes the malignant phenotype. Glycobiology 2002; 12:37R-42R.